The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease
Open accessAbstract
White matter degeneration is a pathological hallmark of neurodegenerative diseases including Alzheimer's. Age remains the greatest risk factor for Alzheimer's and the prevalence of age-related late onset Alzheimer's is greatest in females. We investigated mechanisms underlying white matter degeneration in an animal model consistent with the sex at greatest Alzheimer's risk. Results of these analyses demonstrated decline in mitochondrial respiration, increased mitochondrial hydrogen peroxide production and cytosolic-phospholipase-A2 sphingomyelinase pathway activation during female brain aging. Electron microscopic and lipidomic analyses confirmed myelin degeneration. An increase in fatty acids and mitochondrial fatty acid metabolism machinery was coincident with a rise in brain ketone bodies and decline in plasma ketone bodies. This mechanistic pathway and its chronologically phased activation, links mitochondrial dysfunction early in aging with later age development of white matter degeneration. The catabolism of myelin lipids to generate ketone bodies can be viewed as a systems level adaptive response to address brain fuel and energy demand. Elucidation of the initiating factors and the mechanistic pathway leading to white matter catabolism in the aging female brain provides potential therapeutic targets to prevent and treat demyelinating diseases such as Alzheimer's and multiple sclerosis. Targeting stages of disease and associated mechanisms will be critical.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 2×
“The bioenergetic system of the brain is compromised early in the progression of AD and is evident during the prodromal (preclinical) stage of the disease (Mosconi, 2005; Mosconi et al., 2006, 2009b; Reiman et al., 1996, 2004; Yao et al., 2009, 2011b; Brinton et al., 2015; Moreira et al., 2006; Lin and Beal, 2006).”
Background2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“Age remains the greatest risk factor for developing AD (Hansson et al., 2006; Alzheimer's, 2015).”
BackgroundReiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366 · cited 3×
“Glucose hypometabolism (Mosconi, 2005; Mosconi et al., 2006, 2009b; Reiman et al., 1996, 2004) and a compensatory shift to an alternative fuel substrate, ketone bodies, have been established as a metabolic phenotype characteristic of the AD brain in both clinical and preclinical studies (Yao et…”
BackgroundDiffusion tensor imaging of white matter tract evolution over the lifespan
Lebel, C., Gee, M., Camicioli, R., Wieler, M., Martin, W., & Beaulieu, C. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.094 · Cited by 1,100
Blalock, E. M., Geddes, J. W., Chen, K. C., Porter, N. M., Markesbery, W. R., & Landfield, P. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308512100 · Cited by 1,025
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 3×
“Glucose hypometabolism (Mosconi, 2005; Mosconi et al., 2006, 2009b; Reiman et al., 1996, 2004) and a compensatory shift to an alternative fuel substrate, ketone bodies, have been established as a metabolic phenotype characteristic of the AD brain in both clinical and preclinical studies (Yao et…”
BackgroundLinking lipids to Alzheimer's disease: cholesterol and beyond
Di Paolo, G., & Kim, T.-W. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3012 · Cited by 972
Cited by
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing
Cunnane, S. C., Trushina, E., Morland, C., Prigione, A., Casadesus, G., Andrews, Z. B., Beal, M. F., Bergersen, L. H., Brinton, R. D., de la Monte, S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0072-x · Cited by 1,003
Self-citationAge, APOE and sex: triad of risk of Alzheimer’s disease.
Riedel, B. C., Thompson, P. M., & Brinton, R. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.012 · Cited by 627
Self-citationBrain aging and neurodegeneration: from a mitochondrial point of view
Grimm, A., & Eckert, A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14037 · Cited by 563
An expanded set of genome-wide association studies of brain imaging phenotypes in UK Biobank
Smith, S. M., Douaud, G., Chen, W., Hanayik, T., Alfaro-Almagro, F., Sharp, K., & Elliott, L. T. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00826-4 · Cited by 558
Yin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Self-citationEnergy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Myelin Fat Facts: An Overview of Lipids and Fatty Acid Metabolism
Poitelon, Y., Kopec, A. M., & Belin, S. (2020) · Cells · doi:10.3390/cells9040812 · Cited by 394
“These principles may be translated into therapeutic opportunities for neuropathies either associated with myelin deficits or extended to disorders associated with white matter defects [171,172].”
BackgroundLipid droplets in the nervous system
Ralhan, I., Chang, C.-L., Lippincott-Schwartz, J., & Ioannou, M. S. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202102136 · Cited by 281
“This includes during aging, when myelin is degraded and/or catabolized (Klosinski et al., 2015), and during development, when large Table 1.”
BackgroundApplication of Metabolomics in Alzheimer’s Disease
Wilkins, J. M., & Trushina, E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2017.00719 · Cited by 268
Self-citationMyelin dynamics: protecting and shaping neuronal functions
Saab, A. S., & Nave, K.-A. (2017) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2017.09.013 · Cited by 259
McCarthy, M., & Raval, A. P. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01998-9 · Cited by 254
Oligodendroglial fatty acid metabolism as a central nervous system energy reserve
Asadollahi, E., Trevisiol, A., Saab, A. S., Looser, Z. J., Dibaj, P., Ebrahimi, R., Kusch, K., Ruhwedel, T., Möbius, W., Jahn, O., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01749-6 · Cited by 130
“In mammalian brains, ketone bodies increase with age 39 and can spread horizontally 40 such as pyruvate or lactate through the monocarboxy-late transporter MCT1.”
BackgroundLinking mitochondrial dysfunction, metabolic syndrome and stress signaling in Neurodegeneration
Jha, S. K., Jha, N. K., Kumar, D., Ambasta, R. K., & Kumar, P. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.06.015 · Cited by 122
Glucose metabolism and AD: evidence for a potential diabetes type 3
González, A., Calfío, C., Churruca, M., & Maccioni, R. B. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00996-8 · Cited by 112
Gamache, J., Yun, Y., & Chiba-Falek, O. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.045211 · Cited by 84
Oligodendroglial Energy Metabolism and (re)Myelination
Tepavčević, V. (2021) · Life · doi:10.3390/life11030238 · Cited by 57
“Interestingly, a study of aging in the female brain reported that white matter lipids may be used as a source of energy [129], thus suggesting that energy-deprived oligodendrocytes might even oxidize myelin fat to obtain energy for survival.”
BackgroundKong, F., Wu, T., Dai, J., Zhai, Z., Cai, J., Zhu, Z., Xu, Y., & Sun, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205207 · Cited by 54
Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential
Mi, Y., Qi, G., Brinton, R. D., & Yin, F. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8070 · Cited by 43
Self-citationWang, Y., Shang, Y., Mishra, A., Bacon, E., Yin, F., & Brinton, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-65402-5 · Cited by 42
Self-citationZhang, X., Chen, C., & Liu, Y. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01430-x · Cited by 34
White matter damage in Alzheimer’s disease: contribution of oligodendrocytes
Zhou, J., Zhang, P., Zhang, B., & Kong, Y. (2022) · Current Alzheimer Research · doi:10.2174/1567205020666221021115321 · Cited by 18
“tential therapeutic target for the prevention and treatment of demyelinating diseases, such as AD and multiple sclerosis [51].”
BackgroundInfluential
Metadata
- Authors
- Klosinski, L. P., Yao, J., Yin, F., Fonteh, A. N., Harrington, M. G., Christensen, T. A., Trushina, E., & Brinton, R. D.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 2
- Issue
- 12
- Pages
- 1888-1904
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2187014633
- Cited by
- 164
- References
- 31
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.